renal impairment

[키워드] 1:1 access acute respiratory syndrome addition age anticipated assigned Asymptomatic Baltimore baseline blinded blocked Bone marrow Boston Care Chloroquine clinically suspected close contact Complete Compound Concomitant concomitant use conducted Contact coronavirus coronavirus disease cough COVID-19 criteria current Date defined determine Diagnosis disorder dissemination Efficacy element eligible eligible participant etiology excluded first dose HCQ Health care worker healthcare worker history Hospitalized household household contact Hydroxychloroquine hypersensitivity incidence index case Infection Intervention leukocyte Los Angele medication moderate multisite neutropenia New Orlean New York City number objective outcome participant PCR-confirmed Pharmacist polymerase chain polymorphonuclear Post-exposure prophylaxis Prevent Primary outcome prolonged exposure Prophylaxis protocol psoriasis randomised randomised controlled trial randomization Randomized receive receiving Registered registry renal impairment responders resulting Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR test Seattle Secondary objective Seven severe liver disease Shortness of breath statistical statistician stratified study drug study period Study protocol subjective fever syndrome Tamoxifen telehealth therapy Tolerability Treatment Trial Vaccine virus website women
[DOI] 10.1186/s13063-020-04446-4 PMC 바로가기 [Article Type] Letter